Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ...
Jan 22, 2026 · The median OS for patients receiving relacorilant was 16.0 months, compared to 11.9 months for patients receiving nab-paclitaxel alone, a difference of 4.1 months. Relacorilant in …
Corcept racks up phase 3 cancer win to bounce back from FDA blow
Jan 22, 2026 · Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim data published last year and giving the biotech momentum …
Relacorilant Demonstrates Significant OS in Platinum-Resistant …
Jan 23, 2026 · The ROSELLA trial showed a 35% reduction in death risk and a 4.1-month OS improvement with relacorilant plus nab-paclitaxel. The combination therapy also achieved a 30% …
Corcept’s Phase 3 ROSELLA Trial Shows Significant Survival Benefit...
Jan 22, 2026 · Data showed patients receiving relacorilant achieved a median overall survival (OS) of 16.0 months compared to 11.9 months for standard therapy—an improvement of 4.1 months.
Dr Olawaiye on Updated OS Data With Relacorilant Plus Nab …
Feb 4, 2026 · Alexander B. Olawaiye, MD, discusses updated OS data from the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in PROC.
Corcept's relacorilant delivers Phase III OS win in ovarian cancer
Jan 22, 2026 · Having already significantly delayed disease progression in a Phase III ovarian cancer trial, Corcept Therapeutics said its experimental treatment has now also shown it can extend the …
Corcept’s stock up as relacorilant meets OS goal in Phase III ovarian ...
Jan 22, 2026 · Corcept Therapeutics’ stock has risen 14% after its selective cortisol modulator relacorilant met its overall survival (OS) goal in a Phase III trial in ovarian cancer.
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with ...
Jun 2, 2025 · An interim analysis of overall survival (OS), showed that the addition of relacorilant reduced the risk of death by 31 percent, substantially lengthening patients’ lives.
ROSELLA GOG-3073 | ENGOT-OV72 Corcept Therapeutics …
Mar 31, 2025 · At an interim evaluation of overall survival (OS), patients treated with relacorilant plus nab-paclitaxel had a significant improvement in OS, with a median OS of 16.0 months, compared to …
Ovarian cancer data restores faith in Corcept's relacorilant
Jan 23, 2026 · Now, it has overall survival (OS) data to back up that result, building the case for relacorilant in ovarian cancer ahead of an FDA decision that has an action date of 11th July. The …